Besides, flavonoid apigenin could connect and block adenine nucleotide translocase-2 (ANT2) activation, which led to inducing TRAIL-mediated apoptosis by DR5 up-regulating in TRAIL-resistance tumor cells, and thereby implying that ANT2 inhibitors may contribute to TRAIL therapy due to the ANT2 negative effects on DR5 expression on tumor cells (127). The gene discussed is TNFSF10; the disease is neoplasm.